Compare Build A Bear Workshop Inc (BBW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Summit Therapeutics Inc — how do they compare? Build A Bear Workshop Inc trades at $37.42 (market cap $461.88M), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 26.1× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BBW | SMMT | |
|---|---|---|
Market Cap | $461.88M | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $26.98 |
52-Week Low | $29.84 | $12.55 |
Enterprise Value | $561.32M | $11.39B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $37.10, down 0.43% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 10.48% net margin and 35.87% ROE, supported by recent earnings beats. A new CEO transition and Halloween product launches aim to drive engagement, while analyst consensus is strongly bullish with a $62.50 price target.
BBW presents a compelling value opportunity with a low P/E of 8.63 and consistent earnings outperformance, though near-term revenue headwinds and consumer caution pose risks. The stock's 72.7% buy rating and debt-free balance sheet underpin upside potential, but investors should monitor execution of growth initiatives amid economic pressures.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
